Kura Oncology, Inc.

NasdaqGS:KURA Stock Report

Market Cap: US$689.0m

Kura Oncology Management

Management criteria checks 3/4

Kura Oncology's CEO is Troy Wilson, appointed in Mar 2015, has a tenure of 9.75 years. total yearly compensation is $5.25M, comprised of 12.3% salary and 87.7% bonuses, including company stock and options. directly owns 0.75% of the company’s shares, worth $5.14M. The average tenure of the management team and the board of directors is 4 years and 9.2 years respectively.

Key information

Troy Wilson

Chief executive officer

US$5.3m

Total compensation

CEO salary percentage12.3%
CEO tenure9.8yrs
CEO ownership0.7%
Management average tenure4yrs
Board average tenure9.2yrs

Recent management updates

Recent updates

Kura Oncology Presents Deep Value At Today's Prices (Rating Upgrade)

Dec 18

Kura Oncology: A Contender In The Field Of Precision Medicine

Nov 21

Kura Oncology (NASDAQ:KURA) Has Debt But No Earnings; Should You Worry?

Nov 01
Kura Oncology (NASDAQ:KURA) Has Debt But No Earnings; Should You Worry?

Kura Oncology: The Long Holding Pattern Is Risky

Aug 12

Estimating The Fair Value Of Kura Oncology, Inc. (NASDAQ:KURA)

Jul 12
Estimating The Fair Value Of Kura Oncology, Inc. (NASDAQ:KURA)

Is Kura Oncology (NASDAQ:KURA) Using Debt Sensibly?

May 08
Is Kura Oncology (NASDAQ:KURA) Using Debt Sensibly?

Kura Oncology: Balancing Act Of Promise And Pragmatism

May 07

Kura Oncology: Ziftomenib's Path To AML Market Widens

Jan 31

Kura Oncology, Inc.'s (NASDAQ:KURA) Intrinsic Value Is Potentially 72% Above Its Share Price

Jan 25
Kura Oncology, Inc.'s (NASDAQ:KURA) Intrinsic Value Is Potentially 72% Above Its Share Price

Is Kura Oncology (NASDAQ:KURA) A Risky Investment?

Aug 14
Is Kura Oncology (NASDAQ:KURA) A Risky Investment?

Is Kura Oncology (NASDAQ:KURA) Using Debt Sensibly?

Apr 04
Is Kura Oncology (NASDAQ:KURA) Using Debt Sensibly?

Is There An Opportunity With Kura Oncology, Inc.'s (NASDAQ:KURA) 44% Undervaluation?

Jan 31
Is There An Opportunity With Kura Oncology, Inc.'s (NASDAQ:KURA) 44% Undervaluation?

Kura Oncology (NASDAQ:KURA) Is In A Good Position To Deliver On Growth Plans

Oct 10
Kura Oncology (NASDAQ:KURA) Is In A Good Position To Deliver On Growth Plans

Kura Oncology stock rises 7% as Cantor Fitzgerald begins coverage with Overweight rating

Jul 13

We Think Kura Oncology (NASDAQ:KURA) Can Afford To Drive Business Growth

Jun 26
We Think Kura Oncology (NASDAQ:KURA) Can Afford To Drive Business Growth

We're Not Very Worried About Kura Oncology's (NASDAQ:KURA) Cash Burn Rate

Nov 23
We're Not Very Worried About Kura Oncology's (NASDAQ:KURA) Cash Burn Rate

We're Not Very Worried About Kura Oncology's (NASDAQ:KURA) Cash Burn Rate

Aug 09
We're Not Very Worried About Kura Oncology's (NASDAQ:KURA) Cash Burn Rate

Kura Oncology Investor Presentation - Slideshow

May 08

What Kind Of Shareholders Hold The Majority In Kura Oncology, Inc.'s (NASDAQ:KURA) Shares?

Dec 14
What Kind Of Shareholders Hold The Majority In Kura Oncology, Inc.'s (NASDAQ:KURA) Shares?

Kura Oncology: Advanced Precision Medicine Opportunity Excites, But Not Without Risks

Dec 10

Kura Oncology (KURA) Presents At ASH Virtual Investor Event

Dec 08

CEO Compensation Analysis

How has Troy Wilson's remuneration changed compared to Kura Oncology's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2024n/an/a

-US$198m

Jun 30 2024n/an/a

-US$182m

Mar 31 2024n/an/a

-US$168m

Dec 31 2023US$5mUS$646k

-US$153m

Sep 30 2023n/an/a

-US$143m

Jun 30 2023n/an/a

-US$140m

Mar 31 2023n/an/a

-US$137m

Dec 31 2022US$5mUS$621k

-US$136m

Sep 30 2022n/an/a

-US$135m

Jun 30 2022n/an/a

-US$133m

Mar 31 2022n/an/a

-US$132m

Dec 31 2021US$9mUS$600k

-US$130m

Sep 30 2021n/an/a

-US$124m

Jun 30 2021n/an/a

-US$114m

Mar 31 2021n/an/a

-US$101m

Dec 31 2020US$4mUS$573k

-US$90m

Sep 30 2020n/an/a

-US$81m

Jun 30 2020n/an/a

-US$74m

Mar 31 2020n/an/a

-US$68m

Dec 31 2019US$3mUS$542k

-US$63m

Sep 30 2019n/an/a

-US$61m

Jun 30 2019n/an/a

-US$60m

Mar 31 2019n/an/a

-US$60m

Dec 31 2018US$5mUS$526k

-US$60m

Sep 30 2018n/an/a

-US$55m

Jun 30 2018n/an/a

-US$49m

Mar 31 2018n/an/a

-US$43m

Dec 31 2017US$2mUS$472k

-US$35m

Compensation vs Market: Troy's total compensation ($USD5.25M) is above average for companies of similar size in the US market ($USD3.24M).

Compensation vs Earnings: Troy's compensation has been consistent with company performance over the past year.

CEO

Troy Wilson (55 yo)

9.8yrs

Tenure

US$5,251,407

Compensation

Dr. Troy Edward Wilson, Ph D., J.D., is Independent Director of Cartography Biosciences, Inc. from October 2024. He is Co-Founder of Avidity Biosciences Inc. and had been its Executive Chairman since Febru...

Leadership Team

NamePositionTenureCompensationOwnership
Troy Wilson
Chairman9.8yrsUS$5.25m0.75%
$ 5.1m
Kathleen Ford
Chief Operating Officer5.3yrsUS$2.16m0.016%
$ 108.4k
Teresa Bair
Chief Legal Officer & Corporate Secretary3.2yrsUS$1.98m0.0069%
$ 47.7k
Stephen Dale
Chief Medical Officer4.3yrsUS$2.47m0.0039%
$ 26.8k
Thomas Doyle
Senior Vice President of Finance & Accounting2.8yrsno data0.015%
$ 105.2k
Pete De Spain
Executive Vice President of Investor Relations & Corporate Communications7.2yrsno datano data
Roger Bakale
Senior Vice President of Manufacturing & Supply Chain4.9yrsno datano data
Maureen Clancy
VP and Global Head of Program Leadership & Project Management3.8yrsno datano data
Mollie Leoni
Executive Vice President of Clinical Development2.8yrsno datano data
Brian Powl
Chief Commercial Officer1.3yrsno datano data
Francis Burrows
Senior Vice President of Translational Researchno datano datano data

4.0yrs

Average Tenure

53yo

Average Age

Experienced Management: KURA's management team is considered experienced (4 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Troy Wilson
Chairman9.8yrsUS$5.25m0.75%
$ 5.1m
Daniel Von Hoff
Clinical Advisorno datano datano data
Thomas Malley
Independent Director9.2yrsUS$275.69k0%
$ 0
Mary Szela
Independent Director6.1yrsUS$279.80k0%
$ 0
Faheem Hasnain
Lead Independent Director9.7yrsUS$300.54k0.031%
$ 212.5k
Frank McCormick
Scientific Advisorno datano datano data
Neal Rosen
Scientific Advisorno datano datano data
Kevan Shokat
Chairman of the Scientific Advisory Boardno datano datano data
Alan Houghton
Clinical Advisorno datano datano data
Josep Tabernero
Clinical Advisorno datano datano data
Steven Horwitz
Clinical Advisorno datano datano data
Carol Schafer
Independent Director3.5yrsUS$279.05k0%
$ 0

9.2yrs

Average Tenure

63.5yo

Average Age

Experienced Board: KURA's board of directors are considered experienced (9.2 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/24 16:23
End of Day Share Price 2024/12/24 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Kura Oncology, Inc. is covered by 21 analysts. 14 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Peter LawsonBarclays
Jason ZemanskyBofA Global Research
Leah Rush CannBrookline Capital Markets